Skip to main content
NCBI home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 1997 Apr-Jun;39(2):154–159.

OBSESSIVE COMPULSIVE NEUROSIS : CLOMIPRAMINE, PROLACTIN AND THERAPEUTIC RESPONSE

Jambur Ananth *,*, Amrit Kaur †, Russell Poland ‡, Marcy Wohl §
PMCID: PMC2967101  PMID: 21584063

Abstract

This study was designed to assess the relationship between psychopathology and serotonin generated prolactin response to clomipramine and to assess the relationship between improvement in psychopathology and prolactin levels. The experimental sample consisted of 15 patients in the drug and 12 patients in the placebo groups. Blood samples for prolactin levels were drawn at baseline, and at the end of 4,8, and 12 weeks. There were statistically significant differences in prolactin increase between the drug and the placebo groups at 4 but not at 12 weeks following treatment. When the four least improved and a similar number of the most improved patients were compared, the least improved patients had the most increase in prolactin and the most improved had the least increase.

Keywords: Clomipramine, obsessive compulsive neurosis, prolactin response to clomipramine

Full Text

The Full Text of this article is available as a PDF (269.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barr L. C., Goodman W. K., Price L. H., McDougle C. J., Charney D. S. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry. 1992 Apr;53 (Suppl):17–28. [PubMed] [Google Scholar]
  2. Ben-Jonathan N., Arbogast L. A., Hyde J. F. Neuroendocrine [corrected] regulation of prolactin release. Prog Neurobiol. 1989;33(5-6):399–447. doi: 10.1016/0301-0082(89)90008-7. [DOI] [PubMed] [Google Scholar]
  3. Charney D. S., Goodman W. K., Price L. H., Woods S. W., Rasmussen S. A., Heninger G. R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988 Feb;45(2):177–185. doi: 10.1001/archpsyc.1988.01800260095012. [DOI] [PubMed] [Google Scholar]
  4. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992 Oct;7 (Suppl 2):37–41. doi: 10.1097/00004850-199210002-00007. [DOI] [PubMed] [Google Scholar]
  5. Dubovsky S. L., Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry. 1995;56 (Suppl 2):38–48. [PubMed] [Google Scholar]
  6. Freeman C. P., Trimble M. R., Deakin J. F., Stokes T. M., Ashford J. J. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry. 1994 Jul;55(7):301–305. [PubMed] [Google Scholar]
  7. Goodman W. K., McDougle C. J., Price L. H., Barr L. C., Hills O. F., Caplik J. F., Charney D. S., Heninger G. R. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 1;38(3):138–149. doi: 10.1016/0006-3223(94)00235-U. [DOI] [PubMed] [Google Scholar]
  8. Greist J. H., Jefferson J. W., Kobak K. A., Chouinard G., DuBoff E., Halaris A., Kim S. W., Koran L., Liebowtiz M. R., Lydiard B. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995 Jun;10(2):57–65. doi: 10.1097/00004850-199506000-00001. [DOI] [PubMed] [Google Scholar]
  9. Greist J. H., Jefferson J. W., Kobak K. A., Katzelnick D. J., Serlin R. C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995 Jan;52(1):53–60. doi: 10.1001/archpsyc.1995.03950130053006. [DOI] [PubMed] [Google Scholar]
  10. Hanna G. L., McCracken J. T., Cantwell D. P. Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine. J Am Acad Child Adolesc Psychiatry. 1991 Mar;30(2):173–178. doi: 10.1097/00004583-199103000-00002. [DOI] [PubMed] [Google Scholar]
  11. Hollander E., DeCaria C. M., Nitescu A., Gully R., Suckow R. F., Cooper T. B., Gorman J. M., Klein D. F., Liebowitz M. R. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992 Jan;49(1):21–28. doi: 10.1001/archpsyc.1992.01820010021003. [DOI] [PubMed] [Google Scholar]
  12. Hollander E., Fay M., Cohen B., Campeas R., Gorman J. M., Liebowitz M. R. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988 Aug;145(8):1015–1017. doi: 10.1176/ajp.145.8.1015. [DOI] [PubMed] [Google Scholar]
  13. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humphrey P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994 Jun;46(2):157–203. [PubMed] [Google Scholar]
  14. Insel T. R., Mueller E. A., Alterman I., Linnoila M., Murphy D. L. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985 Nov;20(11):1174–1188. doi: 10.1016/0006-3223(85)90176-3. [DOI] [PubMed] [Google Scholar]
  15. Jenike M. A., Baer L., Summergrad P., Minichiello W. E., Holland A., Seymour R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry. 1990 Jul;147(7):923–928. doi: 10.1176/ajp.147.7.923. [DOI] [PubMed] [Google Scholar]
  16. Lovenberg T. W., Erlander M. G., Baron B. M., Racke M., Slone A. L., Siegel B. W., Craft C. M., Burns J. E., Danielson P. E., Sutcliffe J. G. Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2184–2188. doi: 10.1073/pnas.90.6.2184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lucki I. Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry. 1996;57 (Suppl 6):5–10. [PubMed] [Google Scholar]
  18. López F., González D., Aguilar E. Possible direct effect of serotonin on pituitary prolactin secretion: in vivo and in vitro studies. Horm Res. 1987;25(3):160–170. doi: 10.1159/000180648. [DOI] [PubMed] [Google Scholar]
  19. Montgomery S. A., McIntyre A., Osterheider M., Sarteschi P., Zitterl W., Zohar J., Birkett M., Wood A. J. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol. 1993 Jun;3(2):143–152. doi: 10.1016/0924-977x(93)90266-o. [DOI] [PubMed] [Google Scholar]
  20. Murphy D. L., Zohar J., Benkelfat C., Pato M. T., Pigott T. A., Insel T. R. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry Suppl. 1989 Dec;(8):15–24. [PubMed] [Google Scholar]
  21. Pigott T. A., Hill J. L., Grady T. A., L'Heureux F., Bernstein S., Rubenstein C. S., Murphy D. L. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry. 1993 Jan 1;33(1):3–14. doi: 10.1016/0006-3223(93)90272-f. [DOI] [PubMed] [Google Scholar]
  22. Pigott T. A., Pato M. T., Bernstein S. E., Grover G. N., Hill J. L., Tolliver T. J., Murphy D. L. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry. 1990 Oct;47(10):926–932. doi: 10.1001/archpsyc.1990.01810220042005. [DOI] [PubMed] [Google Scholar]
  23. Pigott T. A., Zohar J., Hill J. L., Bernstein S. E., Grover G. N., Zohar-Kadouch R. C., Murphy D. L. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Mar 1;29(5):418–426. doi: 10.1016/0006-3223(91)90264-m. [DOI] [PubMed] [Google Scholar]
  24. Poland R. E., Rubin R. T. Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin. Life Sci. 1981 Nov 2;29(18):1837–1845. doi: 10.1016/0024-3205(81)90514-2. [DOI] [PubMed] [Google Scholar]
  25. Thorén P., Asberg M., Cronholm B., Jörnestedt L., Träskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry. 1980 Nov;37(11):1281–1285. doi: 10.1001/archpsyc.1980.01780240079009. [DOI] [PubMed] [Google Scholar]
  26. Tollefson G. D., Rampey A. H., Jr, Potvin J. H., Jenike M. A., Rush A. J., kominguez R. A., Koran L. M., Shear M. K., Goodman W., Genduso L. A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul;51(7):559–567. doi: 10.1001/archpsyc.1994.03950070051010. [DOI] [PubMed] [Google Scholar]
  27. Zohar J., Insel T. R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987 Jun;22(6):667–687. doi: 10.1016/0006-3223(87)90199-5. [DOI] [PubMed] [Google Scholar]
  28. Zohar J., Insel T. R., Zohar-Kadouch R. C., Hill J. L., Murphy D. L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988 Feb;45(2):167–172. doi: 10.1001/archpsyc.1988.01800260081011. [DOI] [PubMed] [Google Scholar]
  29. Zohar J., Mueller E. A., Insel T. R., Zohar-Kadouch R. C., Murphy D. L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987 Nov;44(11):946–951. doi: 10.1001/archpsyc.1987.01800230026006. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES